First Quarter 2026 State of Digital Health Funding
Digital health funding hit $7.4B in Q1 2026, the highest since Q2 2022. The CB Insights State of Digital Health report reveals where capital is concentrating and why it matters for pharma leaders.
Reported by CB Insights, global digital health funding reached USD 7.4 billion in the first quarter of 2026, the highest quarterly total since the second quarter of 2022. But the big story is in the data: Where the capital went, how deal structures shifted, and what this means for pharmaceutical and medtech executives.
Digital Health Q1 Headline Numbers
The USD 7.4 billion figure represents a 25% quarter-on-quarter increase from Q4 2025, returning to territory not visited since the peak of the 2022 digital health boom.
Mega-rounds
A continued shift toward larger, later-stage deals, with mega-rounds accounting for 60% of total capital.
Total deal count for Q1 2026 was 336. By historical standards, that is modest. The market processed 905 deals in Q1 2022.
This combination of fewer deals and substantially higher total funding tells the essential story of Q1 2026.
Mega-rounds (individual equity financings of USD 100 million or more) accounted for 60% of all capital deployed across just 19 deals. That is a record share. In Q1 2022, when total funding was USD 11.1 billion, mega-rounds captured 40% of capital.
Commercially Viable Models
Increasing investor focus on commercially viable models rather than purely regulatory or technical milestones.
The inversion is stark: A smaller pool of deals is now absorbing a disproportionately large share of available capital. Average deal size climbed to USD 29.6 million year-to-date in 2026, up 47% year-on-year.
Median deal size for late-stage rounds reached USD 107.5 million in 2026, compared with USD 37.0 million in 2022. For early-stage rounds, median deal size was USD 4.8 million and growing but at a fraction of the pace seen at the late stage.
The market is bifurcating. Proven, commercially mature companies raise more than ever. Earlier-stage companies compete for a limited pool of early capital.
New Unicorns
Strong momentum continues in healthcare AI, particularly in drug discovery.
Eight new digital health unicorns emerged in Q1 2026, the highest single-quarter count since Q2 2022. Seven of the eight were US companies: Grow Therapy (USD 3.0 billion), eMed (USD 2.0 billion), Pomelo Care (USD 1.7 billion), Science (USD 1.5 billion), Garner (USD 1.4 billion), BrainCo (USD 1.3 billion), Midi (USD 1.0 billion), and Solace (USD 1.0 billion).
These domains — mental health, direct-to-patient care, maternal health, neurotechnology, benefit design, and care navigation — illustrate how broad the current investable opportunity set has become.
US Dominance Tightens as Capital Concentrates Geographically
The United States captured USD 5.6 billion of the USD 7.4 billion raised globally in Q1 2026: A 76% share of total funding from 158 deals.
The U.S. represented 47% of the global deal volume, meaning U.S. deals were disproportionately large relative to deal count. Therefore, capital is concentrating by geography as much as in the deal stage.
Silicon Valley remains the densest cluster. Q1 2026 saw USD 1.0 billion deployed across 32 deals, led by Science (USD 230 million Series C), Soley Therapeutics (USD 200 million Series C), and Qualified Health (USD 125 million Series B).
New York deployed USD 1.1 billion across 32 deals, anchored by Talkiatry (USD 210 million Series D), Grow Therapy (USD 150 million Series D), and Garner (USD 118 million Series D). Boston matched New York at USD 1.1 billion across 15 deals, its capital concentrated in fewer, larger rounds.
Europe raised USD 700 million across 89 deals. European deal sizes remain substantially smaller than U.S. equivalents. The median European deal was USD 5.7 million versus USD 9.6 million in the US.
Notable European deals included France's Alan (USD 116 million Series G at a USD 5.8 billion valuation), Germany's Orbem (USD 65 million Series B), and Spain's Biorce (USD 53 million Series A), signalling that capital is reaching beyond the UK and France into the broader European ecosystem.
Asia accounted for USD 848 million across 70 deals, with China leading at USD 596 million from 16 deals. BrainCo (USD 272 million Series B, neurotechnology), Syneron Bio (USD 150 million Series B, therapeutics), and Stairmed (USD 73 million Series C, life sciences) together accounted for nearly USD 500 million of China's total.
India raised USD 145 million across 16 deals, led by Ultrahuman (USD 48 million Series C) and Temple (USD 43 million Seed VC at a USD 187 million valuation).
While these trends point to renewed confidence in the sector globally, the regional distribution of capital remains highly uneven.
Africa, for example, only accounted for approximately USD 4 million in funding across just 3 deals during the same period.
This disparity is not new, but it is becoming more pronounced as capital concentrates in fewer, larger transactions within more mature ecosystems.
From an African perspective, this raises several important considerations: Is the global market increasingly rewarding scale, traction, and clear pathways to commercialisation?
Many African digital health ventures, by contrast, are still operating at early stages and within complex, fragmented health systems that can make rapid scaling more difficult.
A significant proportion of innovation on the African continent is context-specific, addressing challenges such as infectious diseases, maternal and child health, and access to primary care. While highly impactful, these solutions do not always align with the investment models currently dominating global digital health.
M&A Rebounds Sharply: What Buyers Are Actually Paying For
Digital health M&A surged to 56 transactions in Q1 2026, up 47% from 38 in Q4 2025. The rebound represents a significant shift from the subdued exit environment of 2023 and most of 2024.
The most strategically instructive deals tell a consistent story: Buyers are paying premium valuations for demonstrated commercial traction, not merely regulatory clearance.
Abbott's USD 23 billion acquisition of Exact Sciences — the largest deal of the quarter — exemplifies this. Exact Sciences had built a commercially scaled, reimbursed, and clinically validated portfolio anchored by Cologuard, its non-invasive colorectal cancer screening test. Regulatory clearance was table stakes; commercial scale drove the price.
DeepHealth's USD 269 million acquisition of Gleamer, a French AI-powered radiology diagnostics company, illustrates the same dynamic. Gleamer had regulatory clearances for AI-assisted fracture detection across multiple jurisdictions and a deployed customer base across European radiology departments. The acquirer was not paying for the algorithm. It was paying for proven deployment in clinical workflows — a distinction that should sit at the centre of every digital health company's commercial strategy.
Sword's acquisition of Kaia Health (USD 285 million) and Veeva Systems' acquisition of Ostro (USD 100 million) complete the picture. Each involves a commercially deployed product with measurable outcomes, acquired by a strategic buyer accelerating market access rather than building from scratch.
For pharma and medtech business development leaders, the Q1 2026 M&A data reinforces a clear discipline: The gap between regulatory clearance and commercial scale is where valuations are made and broken in the current acquisition market.
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
AI in Drug Discovery: 23% of Quarterly Funding and Growing
One of the most significant sectoral shifts in the first quarter of 2026 is the volume of digital health funding flowing to AI in drug discovery.
The CB Insights data shows that 23% of quarterly digital health funding went to AI-powered drug discovery platforms — a figure that has grown steadily as big pharma partnerships, large funding raises, and early clinical data have legitimised the category.
The quarter's defining deal was Earendil Labs, which raised USD 787 million in private equity backed by Pfizer and Sanofi, making it the single largest equity financing in digital health in Q1 2026. Earendil Labs is building a platform to generate entirely new drug classes through AI-driven molecular design: A bet on generative chemistry as a source of therapeutic novelty, not just optimisation of existing compounds.
Takeda's partnership with Iambic Therapeutics — valued at up to USD 1.7 billion — exemplifies the parallel strategic partnership channel. Large pharma organisations are investing in and partnering with AI drug discovery platforms simultaneously, using equity stakes to secure preferential access to pipeline outputs and co-development arrangements to direct AI capabilities toward priority targets.
Soley Therapeutics raised USD 200 million in a Silicon Valley Series C, positioning itself as a platform for precision oncology programmes built on AI-driven target identification and compound optimisation.
Early-stage bets are equally revealing. Proxima raised USD 80 million in a Seed VC round — an extraordinary seed for any sector — backed by DCVC, Alexandria Venture Investments, and Braidwell, to develop AI-powered novel biological target identification.
Boltz raised USD 28 million at seed stage from Andreessen Horowitz, Amplify Partners, and Zetta Venture Partners to build next-generation protein structure prediction models, operating in the same structural biology territory as AlphaFold3.
The concentration of capital in AI drug discovery is not simply a funding story. It signals that the platform layer (foundation models, structural biology prediction, generative chemistry) is where the industry believes the deepest R&D value will be created.
New drug-class generation, not just drug-candidate optimisation, is where the most ambitious capital is now being deployed.
AI in Diagnostics, Imaging, and Wearables: The Device Opportunity
Beyond drug discovery, the CB Insights data shows sustained investment across the AI-enabled diagnostics, imaging, and wearables categories — the digital health segments most directly relevant to medtech and device-adjacent pharma strategies.
AI-powered diagnostic imaging continues to attract significant capital, driven by demonstrated clinical utility and a growing body of regulatory clearances.
Gleamer's acquisition by DeepHealth — a USD 269 million deal — is the most visible transaction of the quarter in this space. Gleamer's AI platform for fracture detection in radiology had achieved regulatory clearances across multiple jurisdictions and built a customer base of deployed clinical users.
The strategic logic for acquirers is consistent: Imaging AI with regulatory clearance and deployed users commands premium valuations. Algorithms without clinical deployment do not. This distinction is increasingly well understood by investors and shapes which imaging AI companies are fundable at the growth stage.
Wearable health technology continues to attract investment with a direct line to pharmaceutical commercial strategy. Ultrahuman raised USD 48 million in a Series C in India, building continuous metabolic monitoring capabilities that generate longitudinal biomarker data. Temple raised USD 43 million at seed stage at a USD 187 million valuation.
For pharma commercial and medical affairs teams, continuous wearable data creates two strategic opportunities. First, real-world data streams from wearables are increasingly accepted as a component of real-world evidence submissions to regulators and health technology assessment bodies. Second, wearable-connected patient populations represent a channel for adherence monitoring and patient support programme delivery that conventional approaches cannot match.
Neurotechnology is a distinct and growing category within the device-adjacent digital health landscape. BrainCo raised USD 272 million in a Series B in China, representing one of the largest single-round investments in neurotechnology in recent quarters. BrainCo's Q1 2026 valuation of USD 1.3 billion makes it one of eight new unicorns to emerge in the quarter.
The category sits at the intersection of device innovation, neurological disease management, and digital therapeutics — all areas where pharma and device companies are increasingly building or acquiring capability.
Orbem, a German medical imaging startup, raised USD 65 million in a Series B in Q1 2026, developing MRI-compatible imaging platforms with AI-enabled analysis. Germany's sustained presence in the imaging sector reflects the country's deep engineering infrastructure and proximity to European hospital procurement networks with strong medtech purchasing capacity.
Across diagnostics, imaging, and wearables, the Q1 2026 data points to a consistent investment theme: Capital is flowing to companies that combine AI capability with a clear regulatory pathway, demonstrated clinical utility, and a route to reimbursement. Tools that satisfy only one or two of these criteria are struggling to raise at growth stage.
AI in Pharma: Hype vs. What Actually Works
Expert Lara Masad explains why pharma leaders miscalculate AI investments and how to build a defensible validation strategy.
Nvidia: Building the Compute Layer Across Healthcare AI
The CB Insights report highlights Nvidia's strategic positioning across healthcare AI verticals as one of the defining structural developments of Q1 2026.
Over the first four months through March 2026, Nvidia built or extended relationships across care delivery, diagnostics, drug discovery, and surgical robotics, establishing itself as the computing infrastructure layer beneath the AI application stack across multiple digital health categories simultaneously.
This matters for pharma and biotech leaders for a specific reason. Nvidia is not positioning itself as an AI application company in healthcare. It is positioned as the GPU and software infrastructure provider on which AI applications across the industry run.
As AI in drug discovery, AI-assisted diagnostics, and AI-driven clinical trial optimisation scale from early adopters to standard practice, the compute infrastructure supporting those applications becomes a strategic dependency.
For organisations building AI capabilities in-house — whether in R&D, clinical operations, imaging, or supply chain — Nvidia's positioning is relevant to infrastructure planning.
For business development and partnership leaders assessing the competitive landscape, Nvidia's relationships across the digital health ecosystem are a useful map of where established technology partnerships are already being built — and where future platform lock-in may occur.
Prior Authorisation Automation: A Compliance Catalyst for Pharma
The CB Insights report identifies the prior authorisation technology stack as a category mobilising specifically ahead of the U.S. Centers for Medicare and Medicaid Services (CMS) 2027 interoperability deadline.
Prior authorisation — the process by which insurers approve or deny coverage for medications, procedures, and devices before they are provided — is one of the most administratively burdensome and commercially consequential elements of the U.S. healthcare system for pharma manufacturers.
A drug that is technically approved by the FDA but routinely denied through prior authorisation processes struggles to reach patients and generate revenue. The CMS rule mandating electronic prior authorisation under standardised APIs creates a direct regulatory catalyst for investment in the technology infrastructure that processes these decisions.
Multiple companies in the Q1 2026 deal data are building in this space. Anterior (USD 40 million Series B, backed by NEA, Sequoia Capital, and FPV Ventures) is building AI-powered prior authorisation automation for health systems.
Tennr's expansion into prior authorisation processing represents the revenue cycle management player moving into the same space from a different entry point. Garner (USD 118 million Series D), which directs patients to high-performing providers, is indirectly connected to this ecosystem through its impact on care utilisation patterns.
For pharma market access and commercial teams, the CMS 2027 deadline creates a defined catalyst. Electronic prior authorisation with standardised APIs means that data on coverage decisions — which drugs are approved, denied, or appealed, and in which patient populations — will become more structured and potentially more accessible.
This has direct implications for real-world evidence generation, payer relationship strategy, and patient support programme design.
Pharma organisations that engage with the prior authorisation technology stack now will be better positioned to use the resulting data flows strategically when the mandate comes into force.
IPO Market: Selective Signs of Life
The first quarter of 2026 saw four IPOs in digital health globally, a modest but notable figure given that the IPO window was effectively closed through most of 2023 and 2024.
Generate Biomedicines completed the most prominent listing of the quarter, pricing at a USD 2.1 billion valuation. Generate is developing protein-based therapeutics designed entirely by generative AI, extending the AI drug discovery premise directly into the public market.
The small number of IPOs does not represent a reopened window so much as selective entries by companies with sufficiently strong financial profiles to price in the current environment.
The median valuation at IPO for digital health companies in 2026 year-to-date remains below the 2021 peak. Post-IPO performance for digital health stocks has been mixed. A fully reopened IPO market would require sustained public appetite for loss-making growth companies — appetite that has not returned to 2021 levels.
What the Q1 2026 Data Means for Pharma Decision-Makers
Five implications stand out from the CB Insights Q1 2026 data:
First, AI in drug discovery is no longer a speculative category.
Twenty-three percent of quarterly digital health funding going to AI-powered discovery platforms, combined with active big pharma partnership deals from Pfizer, Sanofi, and Takeda, signals that the industry has moved from monitoring to committing.
Pharma organisations without established access to AI discovery capabilities are falling behind the pace at which the field is moving.
Second, commercial traction is the new regulatory approval.
The M&A data from Q1 2026 is unambiguous: Acquirers are paying premium multiples for companies with demonstrated commercial scale, market access, and reimbursement.
For digital health companies developing tools relevant to pharmaceutical workflows — clinical trial recruitment, real-world evidence generation, prior authorisation management — regulatory clearance opens the door, but commercial deployment determines the valuation.
Third, the bifurcation of capital into mega-rounds versus constrained early-stage pools means that the digital health companies best positioned to partner with pharma are those with late-stage funding, large balance sheets, and the commercial maturity to sustain multi-year relationships.
Business development teams should weigh late-stage digital health companies with recent large raises as the most viable near-term partners.
Fourth, the investment signals in diagnostics, imaging, and wearables reflect a maturing market for AI-enabled devices and data tools that connect directly to pharmaceutical R&D and commercial strategy.
Wearable biomarker data is gaining regulatory acceptance as real-world evidence. AI diagnostics are achieving reimbursable deployment. Pharma organisations that engage with these tool categories now — as partners, investors, or data users — will have access to richer clinical and commercial data infrastructure than those that do not.
Fifth, the prior authorisation regulatory catalyst in 2027 will create new data flows and new commercial pressures that will affect pharmaceutical market access strategies.
Organisations that prepare now — by engaging with the technology stack, building relationships with relevant digital health vendors, and assessing the implications for their access and reimbursement strategies — will be better positioned when the deadline arrives.
Pharmatica tracks digital health investment, regulatory catalysts, and AI platform developments across global markets, providing pharmaceutical, biotechnology, and medtech leaders with the evidence-grounded strategic intelligence they need to make informed partnership, investment, and technology decisions in a rapidly evolving landscape.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
How much was raised in digital health funding in Q1 2026?
Global digital health equity funding reached USD 7.4 billion in Q1 2026, the highest quarterly total since Q2 2022, according to the CB Insights State of Digital Health Q1 2026 report. The figure represented a 25% quarter-on-quarter increase from Q4 2025. Total deal count was 336, substantially below the 905 deals recorded in Q1 2022, reflecting a market where capital is concentrating in fewer, larger rounds rather than distributing broadly.
What share of digital health funding went to AI in drug discovery in Q1 2026?
Twenty-three percent of quarterly digital health funding in Q1 2026 went to AI in drug discovery platforms, according to the CB Insights report. The largest single deal was Earendil Labs, which raised USD 787 million backed by Pfizer and Sanofi. Takeda's partnership with Iambic Therapeutics, valued at up to USD 1.7 billion, and Soley Therapeutics' USD 200 million Series C are among the other major deployments in the category.
What is a mega-round in digital health investment?
A mega-round is an individual equity financing of USD 100 million or more. In Q1 2026, mega-rounds accounted for 60% of all digital health capital deployed — a record share — concentrated in just 19 deals. This reflects a structural shift: a smaller number of commercially mature, late-stage companies are raising very large rounds, while the broader early-stage market competes for a constrained pool of smaller financings.
How are AI diagnostics and imaging companies performing in 2026?
AI-enabled diagnostics and imaging companies continue to attract significant capital where they combine regulatory clearance with proven clinical deployment. The quarter's most notable transaction in this category was DeepHealth's USD 269 million acquisition of Gleamer, a French AI radiology company with multi-jurisdictional regulatory clearances and an established European hospital customer base. Orbem, a German medical imaging startup, raised USD 65 million in a Series B, further demonstrating sustained investor interest in AI-enabled imaging platforms with clear regulatory and commercial pathways.
How did digital health M&A perform in Q1 2026?
Digital health M&A activity reached 56 transactions in Q1 2026, a 47% increase from 38 deals in Q4 2025. The largest transaction was Abbott's USD 23 billion acquisition of Exact Sciences. Other notable deals included DeepHealth's USD 269 million acquisition of Gleamer (AI radiology), Sword's USD 285 million acquisition of Kaia Health (digital musculoskeletal therapy), and Veeva Systems' USD 100 million acquisition of Ostro (patient engagement). Across all deals, acquirers consistently paid premium valuations for commercial traction and proven clinical deployment, not regulatory approval alone.
About the author
Did you enjoy the content?
Why not support Nicole Dale by giving this content a like
Comments (0)